ArticleTranslational oncology2026
Pan-cancer analysis identifies FKBP10 as a regulator of tumor immunosuppression and therapeutic response.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumor immune regulation depends on interactions between intrinsic molecular mechanisms, tumor cell metabolic states, and the immune microenvironment. The ER‑localized isomerase FK506‑binding protein 10 (FKBP10) is essential for extracellular matrix homeostasis, but its systemic role in cancer immune regulation and therapeutic response remains unclear.
methodsA pan‑cancer analysis of 33 TCGA tumor types integrated copy number variation, DNA methylation, and mutation data to elucidate FKBP10 regulation. ESTIMATE, ImmuCellAI, and TIMER2 assessed immune infiltration and immunosuppressive phenotypes, and pathway enrichment identified FKBP10‑related metabolic reprogramming, ECM remodeling, EMT, and programmed cell death signals. Therapeutic response was evaluated using breast cancer in vitro assays and GDSC drug sensitivity data.
resultsFKBP10 was significantly upregulated in multiple cancers, especially breast and renal carcinoma, and strongly associated with poor prognosis. Its high expression was mainly driven by promoter hypomethylation and copy number amplification. FKBP10‑high tumors showed enhanced ECM remodeling, metabolic reprogramming, and apoptosis resistance, accompanied by an immunosuppressive microenvironment with reduced cytotoxic T cells and enrichment of myeloid‑derived suppressor cells and cancer‑associated fibroblasts. High FKBP10 expression also correlated with decreased sensitivity to several chemotherapeutic agents. In vitro experiments confirmed that FKBP10 promotes tumor cell proliferation and clonogenicity.
conclusionsFKBP10 is closely linked to tumor progression and treatment response by contributing to metabolic reprogramming, immunosuppressive microenvironment modulation, and programmed cell death regulation, supporting its potential as a biomarker and therapeutic target for predicting prognosis, treatment response, and immunotherapy outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.